secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytoDyn Inc. (CYDY)
CIK:        0001175680
Form:       8-K
Filed at:   2024-04-08T23:59:59+00:00
Accession:  0001558370-24-004802
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

CytoDyn restructures $43.8M Samsung debt; payment contingent on revenue
-----------------------------------------------------------------------

- Total balance of $43,821,231.32 restructured; only $250,000 due by Dec 31, 2024; remainder contingent on 20% of qualifying annual revenue.
- Interest will not accrue on the balance during repayment period; debt is repayable only upon achieving defined 'Revenue' events.
- Letter Agreement terminates Master Services Agreement from April 2019; Samsung will ship specified drug product to storage at CytoDyn’s discretion.
- CytoDyn states it has sufficient drug product and substance for planned clinical activity; will transition manufacturing services to other current providers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175680/000155837024004802/0001558370-24-004802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175680/000155837024004802/cydy-20240403x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer